Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

Inclusion Criteria:

- Men or women 18-65 years of age at time of consent

- Chronic plaque-type psoriasis diagnosed for at least 6 months at time of randomization

- At randomization, moderate to severe psoriasis as defined by:

- PASI score of 12 or greater and,

- IGA score of 3 or greater and,

- Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater.

- Female patients may be included according to the following:

Women of child-bearing potential, defined as all women physiologically capable of becoming
pregnant, using highly effective methods of contraception during dosing and for 5 times the
terminal half-life of study treatment.

• Male subjects must agree to comply with two highly effective contraceptive methods

Exclusion Criteria:

- Forms of psoriasis other than chronic plaque-type (incl. drug induced psoriasis)

- Ongoing use of prohibited psoriasis treatments and other prohibited medication at
randomization. Washout periods detailed in the protocol have to be adhered to

- Previous treatment with IL-17 or IL17R blocking agents, including secukinumab

- Any live vaccines (including nasal-spray flu vaccine) starting from 6 weeks before
screening, during the study, and up to 24 weeks after the last dose of CJM112 or
secukinumab

- Evidence of active tuberculosis at screening

- Active systemic infections (other than common cold)

- Pregnant or nursing (lactating) women